Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
GlaxoSmithKline
Intensity Therapeutics, Inc.
Anaveon AG
Oslo University Hospital
Bristol-Myers Squibb
Ardigen
Ardigen
AbbVie
NYU Langone Health